布地奈德不同给药方式治疗重症肺炎疗效与安全性对比研究  

Comparative Study on Efficacy and Safety of Budesonide in Different Ways for Severe Pneumonia

作　　者：郑新 ZHENG Xin(Jiamusi Central Hospital,Jiamusi 154003,China)

机构地区：[1]黑龙江省佳木斯市中心医院,黑龙江佳木斯154003

出　　处：《中国医学创新》2018年第25期91-95,共5页Medical Innovation of China

摘　　要：目的:探讨布地奈德不同给药方式在重症肺炎患者中的临床疗效及安全性。方法:选择2016年10月-2018年1月入院治疗的重症肺炎患者100例,所有患者均给予布地奈德治疗,根据给药方式分为对照组和观察组,每组各50例。对照组采用布地奈德鼻喷雾剂治疗,观察组采用布地奈德雾化吸入治疗,两组均连续治疗7 d,治疗完毕后对患者效果进行评估。记录并统计两组治疗后退热、咳嗽消失、喘息消失、肺部啰音消失及住院时间;采用酶联免疫吸附试验测定两组治疗前、治疗后7 d白细胞介素-2(IL-2)、白细胞介素-4(IL-4)及干扰素-r(TNF-r)水平;采用免疫速率散射比浊法测定两组治疗前、治疗后7 d免疫球蛋白(Ig)A、M及G水平;记录并统计两组治疗后流鼻涕、口腔溃疡、恶心呕吐、皮疹发生率,比较两组临床治疗效果及药物安全性。结果:治疗后7 d,观察组退热、咳嗽消失、喘息消失、肺部啰音消失及住院时间均短于对照组(P<0.05),IL-2及TNF-r水平均低于对照组(P<0.05),IL-4水平高于对照组(P<0.05),治疗后7 d,观察组IgA水平,均低于对照组(P<0.05),而IgG、IgM水平高于对照组(P<0.05)。治疗后7 d,两组流鼻涕、口腔溃疡、恶心呕吐、皮疹发生率比较差异均无统计学意义(P>0.05)。结论:将布地奈德雾化吸入用于重症肺炎患者中有助于缩短症状改善时间,降低炎症因子水平,药物安全性较高,值得推广应用。To investigate the clinical efficacy and safety of different drug delivery modes of Budesonide in patients with severe pneumonia.Method:100patients with severe pneumonia admitted to hospital from October2016to January2018were enrolled.All patients were treated with Budesonide.According to the mode of administration,they were divided into control group and observation group,with50cases in each group.The control group was treated with budesonide nasal spray.The observation group was treated with Budesonide inhalation.The two groups were treated continuously for7days.The effect of the patients were evaluated after the treatment.The antipyretic,cough disappearance,wheezing disappearance,lung arpake disappearance and hospitalization time were recorded and counted.Before and after treatment7days,the enzyme-linked immunosorbent assay was used to measure interleukin-2(IL-2)interleukin-4(IL-4)and interferon-r(TNF-r)levels;immunoglobulin scatter nephelometry was used to determine immunoglobulin(Ig)A,M and G level;before and after treatment7days,the incidence of runny nose,oral ulcer,nausea and vomiting,rash after treatment in both groups were recorded and counted,the clinical treatment effect and drug safety of the two groups were compared.Result:After treatment7days,the observation group had fever,cough disappearance,wheezing disappeared,lung sputum disappeared,and hospital stay was shorter than the control group(P<0.05).IL-2and TNF-r levels were lower than the control group.(P<0.05),IL-4level was higher than the control group(P<0.05).After treatment7days,the IgA level in the observation group was lower than that in the control group(P<0.05),while the IgG and IgM levels were higher than the control group.(P<0.05).After treatment7days,there was no significant difference in the incidence of runny nose,oral ulcer,nausea and vomiting and rash between the two groups(P>0.05).Conclusion:Inhalation of Budesonide for patients with severe pneumonia can shorten the time of symptom improvement,reduce the level of inflammatory factors

关 键 词：布地奈德雾化吸入 重症肺炎 炎症因子水平 安全性 免疫速率散射比浊法 

分 类 号：R563.1[医药卫生—呼吸系统]